MeSH term
Frequency | Condition_Probility | Acute Disease | 7 | 0.0 |
Adult | 73 | 0.0 |
Bone Marrow Transplantation/*statistics & numerical data | 3 | 3.0 |
Comparative Study | 61 | 0.0 |
Cord Blood Stem Cell Transplantation/*statistics & numerical data | 3 | 3.0 |
Fetal Blood/transplantation | 3 | 3.0 |
Humans | 512 | 0.0 |
Leukemia/*therapy | 3 | 2.0 |
Patient Selection | 3 | 1.0 |
Adolescent | 25 | 0.0 |
Aged | 39 | 0.0 |
Child | 12 | 0.0 |
Child, Preschool | 6 | 0.0 |
Female | 123 | 0.0 |
Infant | 6 | 0.0 |
Male | 90 | 0.0 |
Middle Aged | 56 | 0.0 |
*Diet, Reducing | 2 | 2.0 |
Incidence | 2 | 0.0 |
Reference Values | 3 | 0.0 |
Risk Factors | 8 | 0.0 |
United States/epidemiology | 2 | 0.0 |
Risk | 2 | 0.0 |
Time Factors | 22 | 0.0 |
Aged, 80 and over | 12 | 0.0 |
Balloon Dilatation/adverse effects/*instrumentation | 3 | 7.0 |
Esophageal and Gastric Varices/therapy | 3 | 7.0 |
Esophagus/*injuries/radiography | 3 | 7.0 |
Fatal Outcome | 3 | 0.0 |
Foreign Bodies/*radiography | 3 | 7.0 |
Gastrointestinal Hemorrhage/therapy | 3 | 7.0 |
*Medical Errors | 3 | 6.0 |
Pleural Cavity/*radiography | 3 | 7.0 |
Tomography, X-Ray Computed | 3 | 0.0 |
Combined Modality Therapy | 2 | 0.0 |
Disease Progression | 5 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Adjuvants, Immunologic/*pharmacology | 6 | 3.0 |
Animals | 280 | 0.0 |
Biological Transport | 2 | 0.0 |
Cell Compartmentation | 3 | 0.0 |
Cell Line | 148 | 0.0 |
DNA-Binding Proteins/*metabolism | 3 | 0.0 |
*Drosophila Proteins | 214 | 18.0 |
Lipopolysaccharides/*pharmacology | 56 | 12.0 |
Membrane Glycoproteins/*metabolism | 54 | 10.0 |
Mice | 191 | 0.0 |
Oligodeoxyribonucleotides/*pharmacology | 3 | 9.0 |
Receptors, Cell Surface/*metabolism | 55 | 9.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 342 | 0.0 |
Signal Transduction | 71 | 1.0 |
Antigens, CD14/metabolism | 23 | 19.0 |
Fibroblasts/immunology/metabolism/microbiology | 2 | 100.0 |
Interleukins/metabolism | 2 | 6.0 |
Lipopolysaccharides/*metabolism | 13 | 10.0 |
Membrane Glycoproteins/metabolism | 22 | 3.0 |
Receptors, Cell Surface/metabolism | 22 | 5.0 |
Cell Membrane/metabolism | 7 | 0.0 |
Interleukin-6/biosynthesis | 9 | 4.0 |
Membrane Glycoproteins/*physiology | 44 | 16.0 |
Mice, Inbred C3H | 64 | 9.0 |
Receptors, Cell Surface/*physiology | 47 | 21.0 |
Transfection | 68 | 0.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 31 | 6.0 |
Gene Expression Regulation/*drug effects | 4 | 0.0 |
Nuclear Proteins/*genetics | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 14 | 0.0 |
Tumor Cells, Cultured | 25 | 0.0 |
U937 Cells | 7 | 1.0 |
Antigens, CD14/genetics/*immunology | 2 | 28.0 |
Antigens, Surface/genetics/*immunology | 3 | 27.0 |
Gene Expression | 15 | 0.0 |
Membrane Glycoproteins/genetics/*immunology | 12 | 23.0 |
Molecular Structure | 4 | 0.0 |
Receptors, Cell Surface/genetics/*immunology | 13 | 56.0 |
Species Specificity | 12 | 0.0 |
Antigens, Differentiation/genetics | 3 | 9.0 |
Antigens, Surface/genetics | 4 | 8.0 |
Cells, Cultured | 94 | 0.0 |
Genetic Vectors | 4 | 0.0 |
Membrane Glycoproteins/genetics/*physiology | 15 | 21.0 |
Mice, Inbred C57BL | 56 | 1.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 4 | 1.0 |
Mitogen-Activated Protein Kinase 3 | 6 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 16 | 1.0 |
NF-kappa B/*metabolism | 23 | 3.0 |
Oligonucleotide Array Sequence Analysis | 5 | 0.0 |
Receptors, Cell Surface/genetics/*physiology | 15 | 28.0 |
Receptors, Immunologic/genetics | 2 | 4.0 |
Research Support, U.S. Gov't, P.H.S. | 190 | 0.0 |
*Signal Transduction | 20 | 1.0 |
Transcription Factor AP-1/metabolism | 6 | 2.0 |
Interleukin-1/metabolism | 8 | 3.0 |
Macrophages/metabolism | 9 | 2.0 |
Membrane Glycoproteins/genetics/*metabolism | 35 | 21.0 |
Monocytes/metabolism | 6 | 1.0 |
RNA, Messenger/metabolism | 19 | 0.0 |
Receptors, Cell Surface/genetics/*metabolism | 35 | 25.0 |
Up-Regulation | 21 | 0.0 |
Adjuvants, Immunologic/*physiology | 3 | 9.0 |
CHO Cells | 26 | 1.0 |
Cytokines/secretion | 2 | 2.0 |
Hamsters | 33 | 0.0 |
NF-kappa B/metabolism/physiology | 2 | 25.0 |
Signal Transduction/immunology | 13 | 3.0 |
Antigens, CD14/immunology | 3 | 5.0 |
Bacteria/*immunology | 2 | 11.0 |
Bacterial Infections/*immunology | 3 | 9.0 |
Lipopolysaccharides/*immunology/pharmacology | 4 | 25.0 |
Membrane Glycoproteins/drug effects/immunology | 2 | 40.0 |
Mitogen-Activated Protein Kinase 8 | 3 | 3.0 |
Immunity, Natural/immunology/physiology | 3 | 100.0 |
Membrane Glycoproteins/genetics/metabolism | 3 | 3.0 |
Models, Biological | 14 | 0.0 |
Protein Structure, Tertiary | 21 | 0.0 |
Receptors, Cell Surface/genetics/metabolism | 2 | 3.0 |
DNA Mutational Analysis | 6 | 0.0 |
*Genetic Predisposition to Disease | 8 | 0.0 |
Immunohistochemistry | 15 | 0.0 |
Polymorphism, Genetic | 10 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 30 | 0.0 |
Dose-Response Relationship, Drug | 26 | 0.0 |
Membrane Glycoproteins/*biosynthesis | 5 | 5.0 |
Receptors, Cell Surface/*biosynthesis | 5 | 9.0 |
Infant, Newborn | 5 | 0.0 |
Interferon Type II/*metabolism | 2 | 3.0 |
Lipid A/pharmacology | 8 | 40.0 |
Lymphocyte Activation | 9 | 0.0 |
Membrane Glycoproteins/*agonists | 2 | 33.0 |
Peptidoglycan/pharmacology | 11 | 68.0 |
Receptors, Cell Surface/*agonists | 2 | 22.0 |
Th1 Cells/immunology | 3 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 14 | 0.0 |
Interleukin-6/biosynthesis/genetics | 2 | 5.0 |
Lipopolysaccharides/pharmacology | 59 | 5.0 |
Tumor Necrosis Factor-alpha/analysis/metabolism | 3 | 16.0 |
Drug Tolerance | 6 | 5.0 |
Endotoxins/*toxicity | 3 | 14.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 2 | 1.0 |
Interferon Type II/*pharmacology | 7 | 1.0 |
Kinetics | 5 | 0.0 |
Lipopolysaccharides/*toxicity | 8 | 14.0 |
NF-kappa B/metabolism | 41 | 5.0 |
Tumor Necrosis Factor-alpha/genetics | 2 | 0.0 |
Actins/metabolism | 2 | 0.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Antigens, CD14/*metabolism | 17 | 20.0 |
Cell Adhesion | 3 | 0.0 |
Monocytes/*metabolism | 4 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 40 | 0.0 |
Teichoic Acids/*pharmacology | 4 | 16.0 |
Alleles | 11 | 0.0 |
Case-Control Studies | 10 | 0.0 |
Genotype | 18 | 0.0 |
Membrane Glycoproteins/*genetics | 40 | 9.0 |
*Mutation | 6 | 0.0 |
Receptors, Cell Surface/*genetics | 40 | 13.0 |
Chemokines/biosynthesis | 3 | 7.0 |
Chemokines, CXC/biosynthesis | 2 | 8.0 |
Membrane Glycoproteins/deficiency/genetics/*physiology | 8 | 53.0 |
Mice, Knockout | 46 | 1.0 |
Neutrophils/immunology | 4 | 2.0 |
Phagocytosis | 3 | 0.0 |
Point Mutation | 3 | 0.0 |
Receptors, Cell Surface/deficiency/genetics/*physiology | 8 | 53.0 |
Tumor Necrosis Factor-alpha/analysis | 4 | 0.0 |
Antigens, Surface/chemistry/*metabolism | 2 | 100.0 |
Hela Cells | 11 | 0.0 |
Recombinant Proteins/metabolism | 5 | 0.0 |
Gram-Negative Bacterial Infections/*immunology | 3 | 42.0 |
Immunity, Natural/immunology | 7 | 29.0 |
Receptors, Cell Surface/immunology | 6 | 17.0 |
Genetic Predisposition to Disease | 13 | 0.0 |
Membrane Glycoproteins/genetics | 3 | 1.0 |
Polymorphism, Single Nucleotide | 6 | 1.0 |
Receptors, Cell Surface/genetics | 4 | 3.0 |
Antigens, CD14/genetics | 7 | 35.0 |
*Gene Expression Profiling | 2 | 0.0 |
*Gene Expression Regulation | 8 | 0.0 |
Membrane Glycoproteins/*genetics/*metabolism | 2 | 8.0 |
Postmenopause | 3 | 1.0 |
Receptors, Cell Surface/*genetics/*metabolism | 2 | 14.0 |
*Adaptor Proteins, Signal Transducing | 6 | 0.0 |
Apoptosis/immunology | 3 | 3.0 |
Carrier Proteins/physiology | 6 | 4.0 |
Caspases/antagonists & inhibitors/metabolism | 2 | 2.0 |
Cytokines/biosynthesis | 22 | 4.0 |
Enzyme Activation/immunology | 3 | 2.0 |
Escherichia coli/*immunology | 2 | 5.0 |
Ligands | 28 | 1.0 |
Pregnancy | 6 | 0.0 |
Amino Acid Sequence | 40 | 0.0 |
Molecular Sequence Data | 49 | 0.0 |
Sequence Homology, Amino Acid | 16 | 0.0 |
Signal Transduction/drug effects/*physiology | 2 | 0.0 |
Antigens, Surface/analysis | 2 | 0.0 |
Cell Wall/immunology | 3 | 15.0 |
Interleukin-6/immunology | 4 | 14.0 |
Lipopolysaccharides/immunology | 17 | 14.0 |
NF-kappa B/immunology | 4 | 22.0 |
Peptidoglycan/immunology | 6 | 85.0 |
RNA, Messenger/analysis | 20 | 0.0 |
Receptors, Immunologic/analysis | 3 | 3.0 |
Teichoic Acids/immunology | 3 | 50.0 |
Up-Regulation/immunology | 8 | 5.0 |
Antigens, Differentiation/immunology | 3 | 2.0 |
Antigens, Surface/immunology | 2 | 1.0 |
Membrane Glycoproteins/*immunology | 13 | 7.0 |
Models, Immunological | 5 | 2.0 |
Receptors, Cell Surface/*immunology | 12 | 15.0 |
Receptors, Immunologic/immunology | 2 | 1.0 |
Signal Transduction/*immunology | 22 | 5.0 |
Antigens, Surface/genetics/immunology/*metabolism | 2 | 40.0 |
Endotoxins/*metabolism | 3 | 13.0 |
Lipopolysaccharides/metabolism | 13 | 11.0 |
Membrane Glycoproteins/immunology/*metabolism | 7 | 16.0 |
Receptors, Cell Surface/immunology/*metabolism | 7 | 22.0 |
Gene Expression Regulation | 13 | 0.0 |
Mice, Inbred Strains | 5 | 0.0 |
Binding Sites/physiology | 2 | 1.0 |
Immunity, Natural/physiology | 3 | 27.0 |
Peptidoglycan/metabolism | 2 | 28.0 |
Protein Binding/physiology | 2 | 0.0 |
Signal Transduction/physiology | 11 | 1.0 |
Gene Expression Regulation/drug effects | 6 | 0.0 |
Membrane Glycoproteins/physiology | 9 | 5.0 |
Phosphorylation | 17 | 0.0 |
Protein Kinase C/physiology | 2 | 1.0 |
Receptors, Cell Surface/physiology | 8 | 6.0 |
Sequence Deletion | 4 | 0.0 |
*Acute-Phase Proteins | 7 | 3.0 |
Antigens, CD14/physiology | 9 | 25.0 |
Carrier Proteins/genetics/physiology | 3 | 11.0 |
Cells, Cultured/drug effects/metabolism | 2 | 4.0 |
Cytokines/*biosynthesis/genetics | 3 | 4.0 |
Interleukin-1/biosynthesis/genetics | 2 | 7.0 |
Macrophages, Peritoneal/physiology | 2 | 22.0 |
Specific Pathogen-Free Organisms | 3 | 3.0 |
Tumor Necrosis Factor-alpha/biosynthesis/genetics | 2 | 3.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Signal Transduction/*physiology | 13 | 1.0 |
Tumor Necrosis Factor-alpha/physiology | 3 | 1.0 |
Antigens, Surface/genetics/*metabolism | 4 | 23.0 |
Base Sequence | 25 | 0.0 |
DNA Primers | 8 | 0.0 |
Gene Expression Regulation/*immunology | 3 | 2.0 |
Promoter Regions (Genetics) | 11 | 0.0 |
Amino Acid Substitution | 7 | 0.0 |
Bronchial Provocation Tests | 2 | 2.0 |
Immunity, Natural/*genetics | 2 | 12.0 |
Membrane Glycoproteins/*genetics/metabolism | 7 | 10.0 |
Mutation | 20 | 0.0 |
Mutation, Missense | 7 | 0.0 |
Receptors, Cell Surface/*genetics/metabolism | 7 | 8.0 |
Interferon Type II/pharmacology | 6 | 1.0 |
Macrophage Activation/*physiology | 2 | 8.0 |
Antigens, CD/biosynthesis | 4 | 1.0 |
Biological Markers/analysis | 2 | 0.0 |
Membrane Glycoproteins/*biosynthesis/genetics | 9 | 15.0 |
Polymerase Chain Reaction | 11 | 0.0 |
Receptors, Cell Surface/*biosynthesis/genetics | 9 | 39.0 |
Escherichia coli/pathogenicity | 3 | 33.0 |
Cohort Studies | 6 | 0.0 |
Inhalation Exposure | 2 | 9.0 |
*Polymorphism, Genetic | 20 | 0.0 |
Eosinophils/immunology | 2 | 3.0 |
Immunity, Natural | 16 | 7.0 |
Microscopy, Confocal | 10 | 1.0 |
Cell Differentiation/drug effects | 4 | 0.0 |
Chronic Disease | 4 | 0.0 |
Macrophage Activation/immunology | 2 | 5.0 |
Monocytes/cytology/immunology/metabolism | 2 | 14.0 |
Recombinant Proteins/immunology/metabolism/pharmacology | 2 | 66.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Enzyme Activation | 16 | 0.0 |
Macrophages/drug effects/*metabolism | 2 | 3.0 |
Proto-Oncogene Proteins/metabolism | 5 | 0.0 |
Trans-Activators/metabolism | 4 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 13 | 2.0 |
Antibodies, Monoclonal/pharmacology | 7 | 0.0 |
Antigens, CD14/immunology/metabolism | 3 | 23.0 |
Cytokines/*biosynthesis | 11 | 2.0 |
*Fimbriae Proteins | 2 | 13.0 |
Membrane Glycoproteins/*immunology/metabolism | 2 | 12.0 |
Receptors, Cell Surface/*immunology/metabolism | 4 | 28.0 |
Signal Transduction/drug effects/immunology | 3 | 6.0 |
Drug Interactions | 2 | 0.0 |
Mice, Inbred BALB C | 25 | 0.0 |
Spleen/cytology | 3 | 1.0 |
Antigens, Surface/genetics/physiology | 2 | 40.0 |
Cell Line, Transformed | 8 | 0.0 |
Immunity, Mucosal | 2 | 2.0 |
Interleukin-1/pharmacology | 9 | 1.0 |
NF-kappa B/physiology | 7 | 7.0 |
RNA, Messenger/biosynthesis | 15 | 0.0 |
Cell Separation | 6 | 0.0 |
Flow Cytometry | 26 | 0.0 |
Glycosylation | 6 | 0.0 |
Precipitin Tests | 14 | 0.0 |
Protein Binding | 20 | 0.0 |
Antigens, Differentiation/*biosynthesis | 2 | 6.0 |
Gingiva/cytology/*immunology | 2 | 14.0 |
Interleukin-8/*biosynthesis | 2 | 3.0 |
Receptors, Immunologic/*biosynthesis | 2 | 8.0 |
Endocytosis | 2 | 0.0 |
Receptors, Interleukin-1/*metabolism | 5 | 18.0 |
Down-Regulation | 4 | 0.0 |
Monocytes/*immunology/metabolism | 2 | 5.0 |
NF-kappa B/genetics/metabolism | 7 | 12.0 |
Mitogen-Activated Protein Kinases/*metabolism | 4 | 0.0 |
Interleukin-6/metabolism | 4 | 1.0 |
Lipopolysaccharides/chemistry | 2 | 28.0 |
Molecular Mimicry | 3 | 4.0 |
Structure-Activity Relationship | 8 | 0.0 |
Tumor Necrosis Factor-alpha/metabolism | 10 | 1.0 |
Antigens, Differentiation/*physiology | 4 | 4.0 |
Antigens, Surface/*physiology | 4 | 6.0 |
Dose-Response Relationship, Immunologic | 4 | 0.0 |
Drug Contamination | 2 | 8.0 |
Luciferases/genetics | 3 | 0.0 |
Macrophage Activation/*immunology | 3 | 10.0 |
Receptors, Immunologic/*physiology | 3 | 1.0 |
Antigens, CD14/*biosynthesis/genetics | 3 | 37.0 |
Enzyme Inhibitors/pharmacology | 7 | 0.0 |
HL-60 Cells | 4 | 0.0 |
Macrophages/physiology | 2 | 2.0 |
Phagocytosis/drug effects | 2 | 2.0 |
Trans-Activation (Genetics) | 6 | 0.0 |
Tumor Necrosis Factor-alpha/secretion | 6 | 5.0 |
Cytoplasm/*metabolism | 2 | 1.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Staphylococcus aureus | 2 | 3.0 |
Binding Sites/immunology | 2 | 3.0 |
Heat-Shock Proteins 70/metabolism | 2 | 3.0 |
Heat-Shock Proteins 90/metabolism | 2 | 6.0 |
Nitric Oxide/biosynthesis | 8 | 10.0 |
Protein Binding/immunology | 2 | 1.0 |
Escherichia coli/immunology | 5 | 7.0 |
Membrane Glycoproteins/*biosynthesis/genetics/physiology | 2 | 50.0 |
Receptors, Cell Surface/*biosynthesis/genetics/physiology | 2 | 40.0 |
Staphylococcus aureus/immunology | 4 | 3.0 |
Administration, Inhalation | 3 | 1.0 |
Genetic Predisposition to Disease/*genetics | 3 | 0.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Escherichia coli/metabolism | 5 | 1.0 |
Immunoblotting | 5 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 8 | 1.0 |
Plasmids/metabolism | 7 | 0.0 |
Protein Kinases/metabolism | 10 | 2.0 |
Disease Models, Animal | 3 | 0.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Mutagenesis | 2 | 0.0 |
Cell Differentiation | 6 | 0.0 |
Dendritic Cells/*physiology | 5 | 6.0 |
Macrophages/*physiology | 2 | 2.0 |
Antigens, Surface/physiology | 3 | 7.0 |
Inflammation Mediators/metabolism | 5 | 6.0 |
Macrophages/*immunology | 4 | 1.0 |
Membrane Glycoproteins/genetics/*metabolism/physiology | 2 | 28.0 |
Receptors, Cell Surface/genetics/*metabolism/physiology | 2 | 50.0 |
*Receptors, Interleukin-1 | 2 | 40.0 |
Sepsis/immunology | 3 | 25.0 |
Immunoglobulin E/blood | 2 | 1.0 |
Leukocytes, Mononuclear/immunology | 4 | 1.0 |
Lipopolysaccharides/*immunology | 16 | 21.0 |
Lipopolysaccharides/antagonists & inhibitors/*pharmacology | 6 | 33.0 |
Membrane Glycoproteins/genetics/metabolism/*physiology | 3 | 27.0 |
RNA, Messenger/antagonists & inhibitors/biosynthesis | 2 | 8.0 |
Reactive Oxygen Species/*metabolism | 3 | 1.0 |
Receptors, Cell Surface/genetics/metabolism/*physiology | 3 | 42.0 |
Blotting, Western | 14 | 0.0 |
Cell Line, Tumor | 9 | 0.0 |
Inflammation | 8 | 2.0 |
Transcription, Genetic | 4 | 0.0 |
Antigens, CD14/biosynthesis | 9 | 14.0 |
Liver/metabolism | 2 | 0.0 |
Monocytes | 4 | 4.0 |
Fatty Acids/*pharmacology | 2 | 7.0 |
Blotting, Northern | 5 | 0.0 |
Membrane Glycoproteins/biosynthesis/genetics/*physiology | 2 | 28.0 |
Receptors, Cell Surface/biosynthesis/genetics/*physiology | 2 | 28.0 |
Signal Transduction/genetics/*immunology | 11 | 12.0 |
Antigens, Surface/biosynthesis/genetics/metabolism/*physiology | 2 | 100.0 |
Glycolipids/pharmacology | 2 | 28.0 |
Lipid A/*analogs & derivatives/pharmacology | 5 | 26.0 |
Lipopolysaccharides/*metabolism/pharmacology | 3 | 16.0 |
Antigens, Surface/genetics/metabolism/*physiology | 2 | 100.0 |
Mutagenesis, Site-Directed | 11 | 0.0 |
Bacterial Proteins/*immunology | 2 | 6.0 |
Epithelial Cells/*immunology | 3 | 15.0 |
Interleukin-8/biosynthesis | 9 | 8.0 |
Membrane Glycoproteins/antagonists & inhibitors/*metabolism | 3 | 50.0 |
Oligopeptides/immunology | 2 | 11.0 |
Receptors, Cell Surface/antagonists & inhibitors/*metabolism | 3 | 60.0 |
Lipopolysaccharides/isolation & purification/*pharmacology | 2 | 50.0 |
Membrane Glycoproteins/biosynthesis/genetics | 4 | 8.0 |
Phosphorylation/drug effects | 3 | 0.0 |
Receptors, Cell Surface/biosynthesis/genetics | 3 | 13.0 |
Antibodies, Monoclonal/immunology/pharmacology | 3 | 3.0 |
Interleukin-6/secretion | 2 | 3.0 |
Antigens, CD14/*genetics/metabolism | 2 | 33.0 |
Cytokines/metabolism | 12 | 2.0 |
DNA Primers/chemistry | 2 | 0.0 |
Immunoenzyme Techniques | 4 | 0.0 |
Genes, Reporter | 12 | 0.0 |
*Macrophage Activation | 2 | 3.0 |
*Immunity, Natural | 9 | 15.0 |
DNA-Binding Proteins/metabolism | 6 | 0.0 |
Escherichia coli/*pathogenicity | 2 | 11.0 |
Interleukin-1/biosynthesis | 3 | 1.0 |
Membrane Glycoproteins/analysis/physiology | 2 | 28.0 |
Porphyromonas gingivalis/*pathogenicity | 2 | 33.0 |
Receptors, Cell Surface/analysis/physiology | 2 | 100.0 |
Cell Membrane/immunology/metabolism | 5 | 4.0 |
DNA/metabolism | 2 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 5 | 0.0 |
Mitogen-Activated Protein Kinases/*physiology | 3 | 4.0 |
Antigens, CD14/immunology/*metabolism | 3 | 27.0 |
Brefeldin A/pharmacology | 2 | 2.0 |
Biological Markers/blood | 2 | 0.0 |
Smoking | 2 | 0.0 |
Antibodies/immunology | 2 | 0.0 |
*Up-Regulation | 3 | 1.0 |
Chemokines/metabolism | 2 | 2.0 |
Endoplasmic Reticulum/metabolism | 2 | 0.0 |
CD4-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Drug Synergism | 8 | 0.0 |
Interleukin-12/*biosynthesis | 4 | 11.0 |
Receptors, Chemokine/biosynthesis | 2 | 4.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Carbohydrate Conformation | 2 | 1.0 |
Carbohydrate Sequence | 2 | 0.0 |
Mammals | 2 | 0.0 |
Biological Markers | 3 | 0.0 |
Lipopolysaccharides/immunology/pharmacology | 4 | 19.0 |
Antigens, Differentiation/physiology | 8 | 15.0 |
English Abstract | 4 | 0.0 |
Lipopolysaccharides | 4 | 3.0 |
*Receptors, Immunologic | 12 | 7.0 |
Cell Membrane/*metabolism | 2 | 0.0 |
DNA, Complementary/metabolism | 4 | 0.0 |
Helicobacter pylori/*metabolism | 2 | 12.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Kidney | 4 | 1.0 |
Protein Transport | 5 | 0.0 |
Active Transport, Cell Nucleus | 2 | 0.0 |
Bone Marrow Cells/immunology | 2 | 5.0 |
Interleukin-12/secretion | 2 | 7.0 |
Luciferases/analysis | 2 | 16.0 |
Gene Frequency | 12 | 0.0 |
Genetic Screening | 4 | 0.0 |
Membrane Glycoproteins/*genetics/physiology | 2 | 12.0 |
Odds Ratio | 3 | 0.0 |
Prospective Studies | 5 | 0.0 |
Receptors, Cell Surface/*genetics/physiology | 2 | 15.0 |
Signal Transduction/drug effects | 5 | 0.0 |
Antigens, Differentiation/metabolism | 4 | 3.0 |
Cloning, Molecular | 14 | 0.0 |
CpG Islands | 2 | 0.0 |
Dendritic Cells/immunology | 4 | 2.0 |
Receptors, Cell Surface/antagonists & inhibitors/metabolism/*physiology | 2 | 100.0 |
In Vitro | 16 | 0.0 |
Leukocytes, Mononuclear/drug effects/immunology | 3 | 6.0 |
Lipid A/*analogs & derivatives/*pharmacology | 3 | 60.0 |
Gram-Negative Bacteria/*immunology | 3 | 23.0 |
Gram-Positive Bacteria/*immunology | 2 | 22.0 |
Interleukin-8/genetics | 2 | 3.0 |
Lipopolysaccharides/toxicity | 5 | 6.0 |
Monocytes/immunology | 5 | 1.0 |
Immunity, Cellular | 4 | 0.0 |
Amino Acids/chemistry | 2 | 1.0 |
Evolution | 2 | 0.0 |
Haplotypes | 6 | 0.0 |
Phenotype | 12 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Variation (Genetics) | 6 | 0.0 |
Antigens, CD14/*physiology | 5 | 10.0 |
Carrier Proteins/*physiology | 2 | 0.0 |
Polymyxin B/pharmacology | 6 | 11.0 |
Polymorphism, Genetic/*genetics | 7 | 0.0 |
Severity of Illness Index | 2 | 0.0 |
Antigens, Bacterial/*immunology | 3 | 2.0 |
Antigens, Surface/biosynthesis/genetics | 4 | 36.0 |
Clone Cells | 2 | 0.0 |
Enzyme Activation/genetics/immunology | 2 | 10.0 |
*Immune Tolerance/genetics | 2 | 40.0 |
Mycobacterium tuberculosis/*immunology | 3 | 4.0 |
NF-kappa B/antagonists & inhibitors/metabolism | 4 | 12.0 |
RNA/metabolism | 2 | 0.0 |
Analysis of Variance | 3 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 6 | 0.0 |
Membrane Glycoproteins/*analysis | 5 | 3.0 |
Receptors, Cell Surface/*analysis | 6 | 5.0 |
Sensitivity and Specificity | 3 | 0.0 |
Membrane Glycoproteins/genetics/immunology/*metabolism | 3 | 21.0 |
Mucous Membrane/immunology/metabolism | 2 | 66.0 |
Receptors, Cell Surface/genetics/immunology/*metabolism | 3 | 30.0 |
Bone Marrow Cells | 2 | 0.0 |
Lipopolysaccharides/*chemistry | 2 | 18.0 |
Caco-2 Cells | 5 | 1.0 |
Inflammation/genetics/immunology | 2 | 25.0 |
Interleukin-8/genetics/metabolism | 3 | 14.0 |
Membrane Glycoproteins/*biosynthesis/physiology | 3 | 33.0 |
Receptors, Cell Surface/*biosynthesis/physiology | 3 | 60.0 |
Signal Transduction/genetics/immunology | 6 | 7.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
Carrier Proteins/metabolism | 4 | 0.0 |
Macrophages, Peritoneal/metabolism | 3 | 13.0 |
Membrane Glycoproteins/biosynthesis/*metabolism | 2 | 22.0 |
Monocytes/drug effects/immunology/metabolism | 3 | 15.0 |
Receptors, Cell Surface/biosynthesis/*metabolism | 2 | 15.0 |
Macrophages/immunology | 6 | 2.0 |
Sepsis/*immunology/microbiology | 2 | 100.0 |
Solubility | 8 | 0.0 |
TNF Receptor-Associated Factor 6 | 7 | 5.0 |
Antigens, CD14/genetics/metabolism | 2 | 40.0 |
Antigens, Surface/*genetics/metabolism | 2 | 20.0 |
Genetic Complementation Test | 3 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 5 | 0.0 |
Proteins/physiology | 3 | 2.0 |
Receptors, Interleukin-1/*physiology | 4 | 28.0 |
Macrophage Activation | 5 | 2.0 |
Monocytes/cytology/drug effects/metabolism | 3 | 11.0 |
Isoenzymes/metabolism | 3 | 0.0 |
Superoxides/metabolism | 2 | 0.0 |
Gene Expression Regulation/immunology | 10 | 6.0 |
Monocytes/*physiology | 2 | 1.0 |
Macrophage Activation/*drug effects | 2 | 5.0 |
Lipopolysaccharides/blood | 2 | 9.0 |
Macrophages/*metabolism | 2 | 0.0 |
Phagocytosis/immunology | 3 | 4.0 |
Down-Regulation/genetics/immunology | 2 | 7.0 |
Protein-Serine-Threonine Kinases/physiology | 2 | 2.0 |
Receptors, Interleukin-1/physiology | 2 | 20.0 |
Lipopolysaccharides/immunology/*metabolism | 4 | 57.0 |
Attitude of Health Personnel | 2 | 6.0 |
England | 2 | 1.0 |
Patient Compliance | 2 | 1.0 |
Patient Education | 2 | 3.0 |
Prognosis | 3 | 0.0 |
Age Factors | 3 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Antigens, CD14/*genetics | 5 | 13.0 |
Inflammation/immunology | 6 | 5.0 |
Interleukin-10/biosynthesis | 6 | 5.0 |
Monocytes/*immunology | 5 | 1.0 |
Interleukin-8/metabolism | 8 | 6.0 |
Monocytes/drug effects/*metabolism | 4 | 3.0 |
Fimbriae, Bacterial/*metabolism | 2 | 28.0 |
Macrophages/*drug effects/metabolism | 2 | 5.0 |
NF-kappa B/*physiology | 5 | 5.0 |
Peptidoglycan/*pharmacology | 3 | 50.0 |
Transcription, Genetic/drug effects | 2 | 0.0 |
Dendritic Cells/cytology/*immunology/metabolism | 2 | 15.0 |
Docosahexaenoic Acids/pharmacology | 2 | 22.0 |
Fatty Acids, Unsaturated/*pharmacology | 2 | 6.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 2 | 1.0 |
Macrophages | 3 | 3.0 |
Membrane Glycoproteins/drug effects/*physiology | 3 | 75.0 |
Nitric-Oxide Synthase/genetics | 2 | 5.0 |
Receptors, Cell Surface/drug effects/*physiology | 2 | 16.0 |
Lipoproteins/immunology | 2 | 18.0 |
Membrane Glycoproteins/deficiency/genetics/*immunology | 2 | 100.0 |
Receptors, Cell Surface/deficiency/genetics/*immunology | 2 | 100.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Binding Sites | 5 | 0.0 |
Drosophila | 3 | 0.0 |
Lipopolysaccharides/chemistry/*metabolism | 3 | 42.0 |
Membrane Glycoproteins/chemistry/*metabolism | 3 | 9.0 |
Receptors, Cell Surface/chemistry/*metabolism | 3 | 11.0 |
Recombinant Proteins/chemistry/metabolism | 3 | 0.0 |
Lipopolysaccharides/metabolism/*pharmacology | 5 | 20.0 |
Antigens, Surface/metabolism | 7 | 5.0 |
MAP Kinase Signaling System | 5 | 1.0 |
Active Transport, Cell Nucleus/immunology | 2 | 40.0 |
CD4-Positive T-Lymphocytes/*immunology | 2 | 0.0 |
B-Lymphocytes/immunology | 3 | 0.0 |
T-Lymphocytes/immunology | 4 | 0.0 |
Protein Kinases/*physiology | 3 | 5.0 |
Interleukin-8/secretion | 6 | 15.0 |
Monocytes/*drug effects/metabolism | 2 | 2.0 |
Antibodies, Monoclonal/immunology | 5 | 0.0 |
Membrane Glycoproteins/analysis/metabolism | 2 | 15.0 |
In Situ Hybridization | 3 | 0.0 |
Promoter Regions (Genetics)/immunology | 2 | 2.0 |
Leukocytes, Mononuclear/metabolism | 3 | 1.0 |
Polysaccharides/immunology | 2 | 25.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 4 | 1.0 |
Antigens, CD/metabolism | 4 | 0.0 |
Immunity, Natural/*immunology | 2 | 10.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/physiology | 2 | 15.0 |
Chromones/pharmacology | 2 | 0.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Interleukin-1/physiology | 2 | 2.0 |
Morpholines/pharmacology | 2 | 0.0 |
Lipoproteins/pharmacology | 5 | 22.0 |
Membrane Glycoproteins/biosynthesis/genetics/metabolism/*physiology | 2 | 50.0 |
Receptors, Cell Surface/biosynthesis/genetics/metabolism/*physiology | 2 | 50.0 |
Antibiotics, Peptide/pharmacology | 2 | 7.0 |
Exons | 2 | 0.0 |
Heat | 2 | 0.0 |
Lipopolysaccharides/antagonists & inhibitors/pharmacology | 2 | 9.0 |
Membrane Glycoproteins/chemistry/genetics/*metabolism | 2 | 8.0 |
Rats | 4 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Adjuvants, Immunologic/physiology | 2 | 4.0 |
Immunity, Natural/genetics | 3 | 4.0 |
Multigene Family/immunology | 2 | 8.0 |
RNA, Messenger/genetics | 6 | 0.0 |
Cell Differentiation/immunology | 4 | 1.0 |
Receptors, Interleukin-1/metabolism | 3 | 13.0 |
Cell Line/drug effects/immunology/metabolism | 2 | 100.0 |
*Molecular Mimicry | 2 | 5.0 |
DNA, Complementary/isolation & purification | 2 | 1.0 |
Lipopolysaccharides/*antagonists & inhibitors/*pharmacology | 2 | 40.0 |
Molecular Weight | 3 | 0.0 |
T-Lymphocytes/metabolism | 2 | 0.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors/biosynthesis | 3 | 13.0 |
Membrane Glycoproteins/chemistry/*genetics | 3 | 8.0 |
Receptors, Cell Surface/chemistry/*genetics | 3 | 13.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Cattle | 5 | 0.0 |
Antigens, Surface/*metabolism | 5 | 8.0 |
Substrate Specificity | 2 | 0.0 |
Up-Regulation/genetics/immunology | 4 | 7.0 |
Rabbits | 2 | 0.0 |
Antigen Presentation | 3 | 0.0 |
Lipopolysaccharides/administration & dosage/*pharmacology | 2 | 18.0 |
Organ Specificity/genetics | 2 | 1.0 |
Receptors, Interleukin-1/*immunology | 2 | 40.0 |
Interleukin-10/*biosynthesis | 2 | 3.0 |
Monocytes/immunology/metabolism | 4 | 8.0 |
Microscopy, Fluorescence | 6 | 0.0 |
NF-kappa B/antagonists & inhibitors/*metabolism | 2 | 3.0 |
Cross-Sectional Studies | 2 | 0.0 |
Gene Frequency/genetics | 5 | 1.0 |
Prevalence | 2 | 0.0 |
Risk Assessment | 6 | 0.0 |
I-kappa B/metabolism | 2 | 2.0 |
Open Reading Frames | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 4 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Membrane Glycoproteins/*genetics/*immunology | 2 | 40.0 |
Receptors, Cell Surface/*genetics/*immunology | 2 | 100.0 |
Membrane Glycoproteins/immunology/*physiology | 4 | 23.0 |
Porphyromonas gingivalis/*metabolism | 2 | 50.0 |
Receptors, Cell Surface/immunology/*physiology | 4 | 26.0 |
Signal Transduction/*drug effects | 5 | 1.0 |
Transcription Factors/metabolism | 5 | 0.0 |
Membrane Glycoproteins/deficiency/genetics/physiology | 3 | 75.0 |
Receptors, Cell Surface/deficiency/genetics/physiology | 3 | 100.0 |
Apoptosis | 2 | 0.0 |
Cell Death | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Monocyte Chemoattractant Protein-1/metabolism | 3 | 4.0 |
Prostaglandin-Endoperoxide Synthase/metabolism | 2 | 2.0 |
B-Lymphocytes/drug effects/immunology/metabolism | 2 | 22.0 |
Cytoplasm/metabolism | 3 | 0.0 |
Membrane Glycoproteins/metabolism/*physiology | 6 | 25.0 |
Receptors, Cell Surface/metabolism/*physiology | 6 | 30.0 |
Endotoxins/*pharmacology | 2 | 2.0 |
Symbiosis | 2 | 28.0 |
Interleukin-1/immunology | 2 | 4.0 |
Gene Expression Regulation/*physiology | 3 | 0.0 |
Antigens, CD14/genetics/*metabolism | 2 | 11.0 |
Lipopolysaccharides/antagonists & inhibitors/*metabolism | 2 | 25.0 |
Macrophages/cytology/metabolism | 2 | 8.0 |
Bacteria/*metabolism | 2 | 15.0 |
Blood | 2 | 1.0 |
Gene Expression Profiling | 4 | 0.0 |
Macromolecular Substances | 5 | 0.0 |
Macrophages/immunology/metabolism | 2 | 4.0 |
Membrane Glycoproteins/*metabolism/physiology | 2 | 13.0 |
Receptors, Cell Surface/*metabolism/physiology | 2 | 25.0 |
Conserved Sequence | 2 | 0.0 |
Macrophages, Peritoneal/immunology/metabolism | 4 | 44.0 |
Membrane Glycoproteins/biosynthesis/deficiency/genetics/*physiology | 2 | 66.0 |
NF-kappa B/genetics | 2 | 5.0 |
Receptors, Cell Surface/biosynthesis/deficiency/genetics/*physiology | 3 | 75.0 |
Trans-Activation (Genetics)/immunology | 2 | 8.0 |
Intracellular Signaling Peptides and Proteins/*genetics | 3 | 30.0 |
Neuropsychological Tests | 2 | 0.0 |
Drug Combinations | 2 | 0.0 |
Antibodies, Blocking/pharmacology | 2 | 2.0 |
Down-Regulation/immunology | 4 | 4.0 |
Fluorescence Resonance Energy Transfer | 2 | 4.0 |
Phosphatidylinositols/pharmacology | 2 | 22.0 |
Membrane Glycoproteins/biosynthesis | 2 | 1.0 |
Mice, Transgenic | 7 | 0.0 |
Antigens, CD14/genetics/immunology | 2 | 66.0 |
Membrane Glycoproteins/*genetics/immunology | 3 | 15.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Receptors, Cell Surface/*genetics/immunology | 3 | 42.0 |
Lipopolysaccharides/metabolism/pharmacology | 3 | 16.0 |
Enzyme Activation/drug effects/immunology | 3 | 9.0 |
Protein Biosynthesis | 3 | 0.0 |
Myocardium/*metabolism/pathology | 2 | 7.0 |
Nitric-Oxide Synthase/metabolism | 3 | 2.0 |
Membrane Glycoproteins/biosynthesis/genetics/*immunology | 2 | 28.0 |
Receptors, Cell Surface/biosynthesis/genetics/*immunology | 2 | 100.0 |
Streptococcus pneumoniae/immunology | 2 | 9.0 |
Flagellin/pharmacology | 3 | 42.0 |
Interleukin-8/immunology | 2 | 20.0 |
European Continental Ancestry Group/genetics | 2 | 0.0 |
DNA, Complementary/genetics | 3 | 0.0 |
Endothelium, Vascular/cytology | 2 | 0.0 |
*Gene Expression Regulation, Viral | 2 | 0.0 |
*Immune Tolerance | 3 | 1.0 |
Macrophages, Peritoneal/drug effects/immunology | 2 | 40.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Temperature | 2 | 0.0 |
*Amino Acid Substitution | 2 | 2.0 |
Chromosome Mapping | 5 | 0.0 |
Homozygote | 2 | 0.0 |
Carrier Proteins/chemistry/genetics/*metabolism | 2 | 1.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Lipopolysaccharides/immunology/*metabolism/pharmacology | 2 | 100.0 |
Culture Techniques | 2 | 0.0 |
Th1 Cells/immunology/metabolism | 3 | 7.0 |
Biopsy | 4 | 0.0 |
Epithelial Cells/metabolism | 3 | 0.0 |
Interleukin-12/biosynthesis | 5 | 5.0 |
Immunohistochemistry/methods | 3 | 0.0 |
Arteriosclerosis/*immunology | 2 | 13.0 |
Membrane Glycoproteins/drug effects/*metabolism | 2 | 33.0 |
Proteins/genetics/*physiology | 2 | 1.0 |
Receptors, Cell Surface/drug effects/*metabolism | 2 | 4.0 |
Antigens, CD14/immunology/physiology | 2 | 66.0 |
Membrane Glycoproteins/genetics/immunology/*physiology | 2 | 28.0 |
Receptors, Cell Surface/genetics/immunology/*physiology | 2 | 50.0 |
Receptors, Immunologic/physiology | 7 | 6.0 |
Umbilical Veins/cytology | 3 | 1.0 |
Antigens, Differentiation/genetics/*physiology | 2 | 12.0 |
Receptors, Immunologic/deficiency/genetics/*physiology | 2 | 50.0 |
Lymphocyte Activation/immunology | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Amino Acid Motifs | 3 | 0.0 |
Membrane Glycoproteins/chemistry/*physiology | 2 | 13.0 |
Models, Molecular | 6 | 0.0 |
Protein Folding | 2 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Receptors, Cell Surface/chemistry/*physiology | 2 | 14.0 |
Heterozygote Detection | 2 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Cell Culture Techniques | 2 | 0.0 |
Neutrophils/*physiology | 3 | 2.0 |
Dendritic Cells/cytology/*immunology | 2 | 3.0 |
Protein Subunits/biosynthesis | 3 | 23.0 |
Epithelial Cells/immunology/microbiology | 2 | 66.0 |
Statistics, Nonparametric | 2 | 0.0 |
Body Mass Index | 2 | 0.0 |
Tumor Necrosis Factor-alpha/immunology | 3 | 2.0 |
Interleukin-8/*metabolism | 4 | 7.0 |
Respiratory Burst | 2 | 3.0 |
Cell Degranulation/immunology | 2 | 13.0 |
Cell Division/immunology | 2 | 0.0 |
Receptors, Immunologic/metabolism | 2 | 1.0 |
Cell Membrane/immunology | 3 | 1.0 |
Dendritic Cells/*immunology | 6 | 2.0 |
Neisseria meningitidis/*immunology | 2 | 11.0 |
Membrane Glycoproteins/immunology/metabolism | 2 | 6.0 |
Receptors, Cell Surface/immunology/metabolism | 2 | 13.0 |
Virulence | 2 | 0.0 |
Interferon Type II/immunology | 2 | 2.0 |
Membrane Glycoproteins/immunology | 3 | 1.0 |
Chi-Square Distribution | 2 | 0.0 |
Dimerization | 3 | 0.0 |
Genes, Dominant | 3 | 0.0 |
Isoenzymes/biosynthesis | 2 | 4.0 |
Luciferases/metabolism | 3 | 0.0 |
Prostaglandin-Endoperoxide Synthase/biosynthesis | 2 | 10.0 |
Endothelium, Vascular/*metabolism | 2 | 0.0 |
Microcirculation | 2 | 0.0 |
Cytokines/*metabolism | 4 | 1.0 |
Receptors, Interleukin-1/immunology | 2 | 50.0 |
Gene Expression/physiology | 2 | 0.0 |
Protein Kinases/physiology | 2 | 4.0 |
Oxygen/metabolism | 2 | 0.0 |
Heterozygote | 2 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Genetics, Population | 2 | 0.0 |
Genome, Human | 3 | 0.0 |
Cysteine/*analogs & derivatives/pharmacology | 2 | 28.0 |
Dendritic Cells/*immunology/metabolism | 3 | 6.0 |
Interleukin-12/antagonists & inhibitors/biosynthesis | 2 | 28.0 |
Leukocytes, Mononuclear/immunology/metabolism | 2 | 4.0 |
Poly I-C/pharmacology | 2 | 8.0 |
Bacterial Proteins/immunology | 2 | 9.0 |
Cell Survival/drug effects | 3 | 0.0 |
Interleukin-4/pharmacology | 2 | 0.0 |
Lymphocyte Activation/*immunology | 2 | 0.0 |
*Down-Regulation | 2 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Luminescent Proteins/metabolism | 2 | 0.0 |
Tumor Necrosis Factor-alpha/immunology/metabolism | 2 | 10.0 |
Capsid Proteins/analysis | 2 | 100.0 |
RNA, Viral/analysis | 2 | 0.0 |
*Virus Replication | 3 | 1.0 |
Gram-Negative Bacteria/immunology | 4 | 30.0 |
Gram-Positive Bacteria/immunology | 2 | 40.0 |
Phylogeny | 3 | 0.0 |
Sequence Homology | 2 | 0.0 |
Biological Assay | 2 | 0.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Immune Tolerance | 4 | 1.0 |
Neutrophils/*immunology | 2 | 1.0 |
Receptors, Interleukin-1/chemistry/genetics/*metabolism | 2 | 100.0 |
Adaptor Proteins, Vesicular Transport/*physiology | 2 | 40.0 |
RNA, Double-Stranded/pharmacology | 2 | 28.0 |
RNA/chemistry/genetics | 2 | 7.0 |
Up-Regulation/physiology | 3 | 2.0 |
Antigens, CD14/immunology/*physiology | 3 | 33.0 |
Dipeptides/pharmacology | 2 | 4.0 |
Receptors, Cell Surface/*agonists/*physiology | 2 | 100.0 |
Antigens/*immunology | 2 | 2.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Receptors, CXCR4/metabolism | 2 | 1.0 |
Salmonella/immunology | 2 | 16.0 |
Endotoxins/metabolism | 2 | 14.0 |
Amino Acid Substitution/genetics | 2 | 0.0 |
Candida albicans/immunology | 2 | 4.0 |
DNA-Binding Proteins/metabolism/*physiology | 2 | 1.0 |
Exercise/*physiology | 3 | 0.0 |
CA-15-3 Antigen/chemistry/genetics/*immunology | 3 | 16.0 |
Cancer Vaccines/*immunology | 3 | 5.0 |
Immunization | 3 | 0.0 |
Melanoma, Experimental/immunology/*therapy | 3 | 15.0 |
Tandem Repeat Sequences | 3 | 2.0 |
CpG Islands/immunology | 3 | 23.0 |
Oligodeoxyribonucleotides/metabolism/pharmacology | 2 | 100.0 |
Poly I-C/metabolism/pharmacology | 2 | 100.0 |
Apoptosis/genetics/*immunology | 2 | 11.0 |
Cell Adhesion Molecules/biosynthesis | 2 | 2.0 |
Carrier Proteins/chemistry/*metabolism | 2 | 2.0 |
Antigens, CD14/biosynthesis/metabolism | 2 | 50.0 |
Neoplasms/*immunology | 2 | 1.0 |
Phagocytosis/*physiology | 2 | 4.0 |
Picibanil/*pharmacology | 2 | 11.0 |
Antigens, CD14/analysis | 5 | 4.0 |
Mice, Inbred CBA | 2 | 0.0 |
Transplantation, Homologous | 2 | 0.0 |
Tumor Necrosis Factor-alpha/genetics/metabolism | 5 | 9.0 |
*Protein-Serine-Threonine Kinases | 2 | 0.0 |
Injections, Intraperitoneal | 3 | 2.0 |
Aging/*physiology | 2 | 0.0 |
Interleukin-1/genetics/metabolism | 2 | 11.0 |
Leukocyte Count | 2 | 0.0 |
Antigens, CD14/biosynthesis/genetics | 2 | 28.0 |
Antigens, Differentiation/biosynthesis/genetics | 2 | 22.0 |
Receptors, Immunologic/biosynthesis/genetics | 2 | 33.0 |
Salmonella enterica/immunology | 2 | 100.0 |
Receptors, Chemokine/*metabolism | 2 | 1.0 |
Teichoic Acids/pharmacology | 3 | 23.0 |
Aspartic Acid/*metabolism | 2 | 16.0 |
Follow-Up Studies | 2 | 0.0 |
APACHE | 2 | 3.0 |
Th2 Cells/metabolism | 2 | 4.0 |
Mycobacterium tuberculosis/immunology | 2 | 6.0 |
Down-Regulation/physiology | 2 | 2.0 |
Neutrophil Activation/*physiology | 2 | 13.0 |
Receptors, Immunologic | 2 | 5.0 |
Cytokines/biosynthesis/genetics | 2 | 3.0 |
Evolution, Molecular | 2 | 0.0 |
Acetylmuramyl-Alanyl-Isoglutamine/immunology | 2 | 66.0 |
Monocytes/drug effects/metabolism | 2 | 2.0 |
Linkage Disequilibrium | 2 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
